{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:58:32Z","timestamp":1761562712783},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1038\/s41574-020-00450-5","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T18:03:12Z","timestamp":1606759392000},"page":"73-74","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Shortening the paths to type 1 diabetes mellitus prevention"],"prefix":"10.1038","volume":"17","author":[{"given":"Anette-G.","family":"Ziegler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezio","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"450_CR1","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.2337\/dc19-0593","volume":"42","author":"EK Sims","year":"2019","unstructured":"Sims, E. K. et al. Who is enrolling? The path to monitoring in type 1 diabetes TrialNet\u2019s pathway to prevention. Diabetes Care 42, 2228\u20132236 (2019).","journal-title":"Diabetes Care"},{"key":"450_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold, K. C. et al. An anti-CD3 antibody, Teplizumab, in relatives at risk for type 1 diabetes. N. Engl. J. Med. 381, 603\u2013613 (2019).","journal-title":"N. Engl. J. Med."},{"key":"450_CR3","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.4049\/jimmunol.1900733","volume":"203","author":"M Tahvildari","year":"2019","unstructured":"Tahvildari, M. & Dana, R. Low-dose IL-2 therapy in transplantation, autoimmunity, and inflammatory diseases. J. Immunol. 203, 2749\u20132755 (2019).","journal-title":"J. Immunol."},{"key":"450_CR4","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1007\/s00125-020-05200-w","volume":"63","author":"M Rosenzwajg","year":"2020","unstructured":"Rosenzwajg, M. et al. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I\/II randomised, double-blind, placebo-controlled, dose-finding study. Diabetologia 63, 1808\u20131821 (2020).","journal-title":"Diabetologia"},{"key":"450_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrd3805","volume":"11","author":"C Harrison","year":"2012","unstructured":"Harrison, C. Targeting IL-7 reverses type 1 diabetes. Nat. Rev. Drug Discov. 11, 599 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"450_CR6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126054","volume":"4","author":"KC Herold","year":"2019","unstructured":"Herold, K. C. et al. Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes. JCI Insight 4, e126054 (2019).","journal-title":"JCI Insight"},{"key":"450_CR7","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2337\/diacare.28.5.1068","volume":"28","author":"The Diabetes Prevention Trial-Type Study Group","year":"2005","unstructured":"The Diabetes Prevention Trial-Type Study Group. Effects of oral insulin in relatives of patients with type 1 diabetes. Diabetes Care 28, 1068\u20131076 (2005).","journal-title":"Diabetes Care"},{"key":"450_CR8","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1001\/jama.2017.17070","volume":"318","author":"Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group","year":"2017","unstructured":"Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA 318, 1891\u20131902 (2017).","journal-title":"JAMA"},{"key":"450_CR9","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.2337\/db20-0166","volume":"69","author":"JM Sosenko","year":"2020","unstructured":"Sosenko, J. M. et al. slowed metabolic decline after 1 year of oral insulin treatment among individuals at high risk for type 1 diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet oral insulin prevention trials. Diabetes 69, 1827\u20131832 (2020).","journal-title":"Diabetes"},{"key":"450_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1001\/jama.2019.21565","volume":"323","author":"AG Ziegler","year":"2020","unstructured":"Ziegler, A. G. et al. Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany. JAMA 323, 339\u2013351 (2020).","journal-title":"JAMA"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41574-020-00450-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41574-020-00450-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41574-020-00450-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:48:13Z","timestamp":1684619293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-020-00450-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["450"],"URL":"https:\/\/doi.org\/10.1038\/s41574-020-00450-5","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]},"assertion":[{"value":"30 November 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}